Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.41 |
| ▸ | HTR2C | P28335 | 5/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18538423 | 0.84 | HTR2A (0.39) | HTR2AHTR2CHTR2BBRD4MAPT | |
| SCHEMBL18152794 | 0.79 | PDE4B (0.38) | HTR2AHTR2CHTR2BBRD4MAOA | |
| SCHEMBL18152658 | 0.79 | HTR2A (0.34) | HTR2ABRD4MAPTMEN1KMT2A | |
| SCHEMBL30184587 | 0.78 | S100B (0.45) | BRD4MAPTMAOAMAOBSLC6A4 | |
| SCHEMBL18152739 | 0.76 | EPAS1 (0.42) | BRD4 | |
| SCHEMBL18152737 | 0.74 | BRD4 (0.52) | BRD4 | |
| SCHEMBL18152707 | 0.73 | BRD4 (0.64) | BRD4 | |
| SCHEMBL18152883 | 0.70 | BRD4 (0.49) | BRD4MEN1KMT2A | |
| SCHEMBL31387353 | 0.70 | BRD4 (0.46) | BRD4MEN1KMT2A | |
| SCHEMBL2891420 | 0.70 | BRD4 (0.46) | BRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831383-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3831383-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3283077-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3283077-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10807982-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807982-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-3283077-A2 | BROMODOMAIN INHIBITOR | Celgene Quanticel Research, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2016168682-A2 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168682-A2 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | HTR2A 4372/4885HTR2C 4251/4885HTR2B 4494/4885 |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | BRD3, BRPF3, EP300 | HTR2A 4362/4885HTR2C 4238/4885HTR2B 4472/4885 |
| US-10807982-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | HTR2A 4372/4885HTR2C 4251/4885HTR2B 4494/4885 |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | HTR2A 4372/4885HTR2C 4251/4885HTR2B 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.